Contact
Please use this form to send email to PR contact of this press release:
MEDERA RECEIVES FDA CLEARANCE FOR A FIRST-IN-HUMAN GENE THERAPY TRIAL FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION
TO:
info@medera.bio
Medera, Inc.
(949) 373 5126